Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, reviews the trends from the latest approvals data from the medical devices regulator.
The UK’s medical device sector is entering a period of unprecedented momentum, with new data from the Medicines and Healthcare products Regulatory Agency (MHRA) showing a record number of approved clinical investigations in 2025. Approvals rose 17% compared with 2024, underscoring the UK’s growing appeal as a global testbed for breakthrough technologies – particularly in neurotechnology and artificial intelligence.
For innovators, the message is clear: the UK is positioning itself as one of the world’s most agile and innovation‑ready regulatory environments for medical devices.
Neurotechnology Surges to the Forefront
The most striking growth has come from neurotechnology, where clinical investigations have doubled since 2024 and now represent roughly a quarter of all UK applications. This surge reflects a global push to address complex neurological conditions such as dementia, Parkinson’s disease and epilepsy – areas where traditional treatments often fall short.
Recent MHRA approvals include a feasibility study assessing deep brain stimulation for addiction disorders, as well as a first‑in‑human paediatric trial led by Great Ormond Street Hospital, UCL and the University of Oxford. The latter will test a rechargeable brain‑stimulation implant designed to reduce seizure frequency in children with severe, treatment‑resistant epilepsy.
AI‑Driven Devices Gain Ground
AI‑enabled devices are also accelerating, with new studies exploring tools that detect disease earlier, guide clinical decisions and personalise treatment pathways. Among the latest approvals is a digital therapeutic for chronic obstructive pulmonary disease that dynamically adjusts treatment recommendations in real time. Ophthalmic technologies are another area of rising activity, as companies test new approaches to preserving and restoring vision.
Together, these trends point to a future of faster diagnostics, more precise interventions and earlier access to transformative technologies for patients.
New Measures to Support Smaller Innovators
To sustain this momentum, the MHRA has introduced a package of measures aimed at reducing barriers for smaller companies. From January 2026, micro and small UK‑based firms can access a fee‑waiver pilot designed to unlock early‑stage innovation that might otherwise stall due to cost constraints.
The agency is also participating in a UK‑wide partnership led by Newcastle University to update national guidance on neurotechnology research—an effort expected to streamline study setup for devices interacting with the brain and nervous system.
The author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
Related
link